Pfizer and Gene Logic announced today an initiative whereby Gene Logic will analyze Pfizer candidates which have been dropped from development. The analysis will hopefully surface new indications for candidates which would otherwise never see the light of day. Quote:
"We will be putting Pfizer's selected drug candidates through a diverse battery of technologies specifically designed for drug repositioning," said Dr Louis Tartaglia, general manager and senior vice president of Drug Repositioning for Gene Logic. "Data analysis from those studies will provide a comprehensive picture of the drug candidates' biological activities and determine possible new therapeutic uses for these potential medicines."
This concept of drug "repositioning" or "repurposing" has been batted around for around 5 years. There are a few companies with the capability to do this. One of my favorites is KineMed. This is an important deal and area to monitor.
Comments